Personalis, INC Form 4 insider transactions

Personalis, Inc. announced a definitive agreement to merge with Tempus AI, Inc. in a transaction structured as a two-step merger, with Tempus AI as the acquirer.

Tempus AI announced a definitive agreement to acquire Personalis for $1.5 billion, aiming to enhance its oncology diagnostics and biopharma offerings.

Tempus AI announced its agreement to acquire Personalis, Inc., aiming to integrate genomic data and AI-driven insights.

Tempus AI announced its agreement to acquire Personalis, Inc. for $1.7 billion, aiming to integrate Personalis's ultrasensitive molecular residual disease (MRD) testing into its AI-enabled precision oncology platform.

Tempus AI, Inc. announced its entry into a definitive Agreement and Plan of Merger with Personalis, Inc., outlining the terms of a two-step merger transaction.

Tempus AI announced its definitive agreement to acquire Personalis, Inc. for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Richard Chen, President and CMO of Personalis, Inc., sold 100,000 shares of common stock on July 15, 2026 for $15.15 per share.

Christopher M. Hall, CEO of Personalis, Inc., reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Aaron Tachibana, CFO and COO of Personalis, Inc., reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged Rule 10b5-1 trading plan.

Personalis, Inc. CFO and COO Aaron Tachibana executed a Rule 10b5-1 trading plan, involving the acquisition and sale of company stock.

Personalis CEO Christopher M. Hall reported the sale of 100,000 shares of common stock, acquired through option exercise, as part of a pre-arranged trading plan.

Director Karin Eastham filed an amendment to correct the reported beneficial ownership of common stock following an RSU grant.

CFO and COO Aaron Tachibana exercised options and sold 40,000 shares of Personalis, Inc. common stock under a 10b5-1 plan.

CEO Christopher M. Hall exercised options and sold 100,000 shares of Personalis, Inc. common stock under a pre-arranged 10b5-1 trading plan.

CFO and COO Aaron Tachibana exercised options and sold 38,799 shares of Personalis, Inc. common stock under a 10b5-1 plan.

Director Karin Eastham of Personalis, Inc. reported the acquisition of 6,250 restricted stock units and the grant of stock options for 37,500 shares.

Bowman A. Blaine, a Director at Personalis, Inc. (PSNL), reported transactions involving the acquisition of common stock and stock options.

Director Kenneth Widder acquired 6,250 shares of common stock and 37,500 stock options in Personalis, Inc. on May 12, 2026.

Director Lonnie Shoff of Personalis, Inc. reported the acquisition of 6,250 shares of common stock and the grant of stock options for 37,500 shares.

Director Olivia Kyusuk Bloom reported the acquisition of 6,250 restricted stock units and 37,500 stock options in Personalis, Inc. on May 12, 2026.

Woodrow A. Myers Jr., a Director at Personalis, Inc., reported the acquisition of 6,250 restricted stock units and 37,500 stock options on May 12, 2026.

Personalis, Inc.'s CFO and COO, Aaron Tachibana, was granted 34,375 restricted stock units and options to purchase 206,250 shares of common stock.

Stephen Michael Moore, SVP and Chief Legal Officer of Personalis, Inc., was granted 28,125 restricted stock units and 168,750 stock options.

Personalis CEO Christopher M. Hall received 87,500 restricted stock units and 525,000 stock options, increasing his beneficial ownership.

Personalis, Inc. President and CMO Richard Chen reported the acquisition of restricted stock units and stock options, increasing his beneficial ownership.

Personalis, Inc.'s CFO and COO, Aaron Tachibana, acquired 15,000 performance stock options following the satisfaction of a reimbursement milestone.

Personalis, Inc.'s Chief Medical Officer, Richard Chen, acquired 15,000 stock options at an exercise price of $1.61 following a performance milestone.

Stephen Michael Moore, SVP and Chief Legal Officer of Personalis, Inc., vested 8,333 performance stock options following the achievement of a reimbursement milestone.

Personalis, Inc. CEO Christopher M. Hall vested 33,333 performance stock options at an exercise price of $1.61 following the satisfaction of a reimbursement milestone.

Tempus AI, a significant shareholder and director, increased its beneficial ownership in Personalis, Inc. by acquiring over 320,000 common shares across multiple transactions in late 2025.